- Lobbying
- Kristina AND Dunklin
Lobbying Arrangements Results for 'Kristina Dunklin'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to Medicaid and COVID-19. |
Molina Healthcare, Inc.
|
Forbes-Tate | |||
Details Issues related to privacy legislation. |
Whitepages, Inc.
|
Forbes-Tate | |||
Details Issues related to federal climate policy. |
CEO Climate Dialogue
|
Forbes-Tate | |||
Details Issues related to veterans, defense, Congressional productivity, and national service. Issues related to veterans, defense, and Congressional productivity; Issues regarding implementation of the Na... |
With Honor Action
|
Forbes-Tate | |||
Details Issues related to rare disease, drug development, reimbursement, and market access. |
Ultragenyx Pharmaceutical
|
Forbes-Tate | |||
Details Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program. Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Ant... |
Lilly USA, LLC
|
Forbes-Tate | |||
Details Issues related to global marketing restrictions. Issues related to laboratory developed tests. Issues related to the implementation of H.R. 6147 (115th Congress) - FY 2019 Appropriations; Issues re... |
Abbott Laboratories
|
Forbes-Tate | |||
Details Issues related to Rx pricing; Issues related to plasma and plasma derived therapies. Issues related to legislative and regulatory issues related to gene therapies for hemophilia B; Issues related t... |
CSL Behring
|
Forbes-Tate | |||
Details Issues related to H.R. 4368 - The Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024, climate, trade and agriculture; Issues related to legi... |
U.S. Beet Sugar Association (USBSA)
|
Forbes-Tate | |||
Details Issues related to space launch competition in the National Security Space Program; Issues regarding civil space programs. Issues related to space launch competition in the National Security Space (... |
Space Exploration Technologies Corporation
|
Forbes-Tate | |||
Details Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260). Transportation issues regarding medical transport., Issues related to S. 1939 - F... |
Global Medical Response
|
Forbes-Tate | |||
Details Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency A... |
Independent Pharmacy Cooperative
|
Forbes-Tate | |||
Details Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness. Healthcare initiatives related to novel antibody technology platform. Issues related to p... |
Vir Biotechnology, Inc.
|
Forbes-Tate | |||
Details Issues related to prescription drug pricing; Issues related to proposed regulations affecting Medicare Part D. Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and result... |
Lundbeck LLC
|
Forbes-Tate | |||
Details Issues related to preserving economic balance regarding regulation of the railroad industry; Issues related to 2-man crew site; Issues related to infrastructure and transportation; Issues related t... |
Association of American Railroads
|
Forbes-Tate | |||
Details Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress). |
Coalition for App Fairness
|
Forbes-Tate | |||
Details Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit and issues related to... |
Alexion Pharmaceuticals, Inc.
|
Forbes-Tate | |||
Details Issues related to alternative treatments for PTSD and research in treating behavioral health challenges. |
MAPS Public Benefit Corporation
|
Forbes-Tate | |||
Details Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages. |
A Place for Mom, Inc.
|
Forbes-Tate | |||
Details Issues related to funding and administration of the Low Income Home Energy Assistance Program (LIHEAP); including through FY 2024 Labor, HHS, Education Appropriations; Issues related to LIHEAP Fund... |
Coalition for Energy Assistance Modernization
|
Forbes-Tate | |||
Details Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation. Issues related to energ... |
A.O. Smith Corporation
|
Forbes-Tate | |||
Details Issues pertaining to government-wide federal regulation of cannabis. |
Coalition for Cannabis Policy, Education, and Regulation
|
Forbes-Tate | |||
Details Issues related to FY 2022 Defense Appropriations; Issues related to funding for university research and UARCs. Issues related to emergency funding for institutions of higher education in H.R. 1319 ... |
University of Southern California
|
Forbes-Tate | |||
Details Issues related to Advanced Research Projects Agency-Energy (ARPA-E) funding. Issues related to ARPA-E funding; Issues related to energy innovation. Issues related to increasing financing options; I... |
Capitol Solutions on behalf of Bipartisan Policy Center Advocacy Network, Inc.
|
Forbes-Tate | |||
Details Issues related to broadband spectrum policy, the incentive auction, net neutrality, 5G deployment, rural broadband, and privacy; Supply chain related issues; Issues related to privacy. Issues relat... |
CTIA - The Wireless Association
|
Forbes-Tate | |||
Details Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending ... |
Emergent Biosolutions
|
Forbes-Tate | |||
Details Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of C... |
Novartis, Inc.
|
Forbes-Tate |